+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results



Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results



Minerva Pediatrica 46(5): 225-230



Desferrioxamine (DFO), an iron-chelating drug, up to today has been essential for the care of thalassaemic patients. Unfortunately it presents some toxic effects. One of these is sensorineural hypoacusia, already reported some years ago. In 1987 we documented in our patients a prevalence of 19.4% (7 cases of 36) of sensorineural hypoacusia that proved to be significantly associated with the highest pro kg/die doses of DFO. We made a follow-up audiometry over a 5-year period after a general adjustment of the DFO dosage related to serum Ferritin levels. Four patients with mild hypoacusia (30-50 dB) showed normal audiometry after one year. The hypoacusia of the two severe cases (50-80 dB) proved stable until 5-years later in one case and increased in the other. Only a new case arose denovo. In pathologic patients "Therapeutic index" (DFO/serum Ferritin) was significantly higher than in normoacusic ones and the "threshold" value between the two populations was of 0.027. We think that the Therapeutic index may be a useful guideline to calculate safe doses of DFO about ototoxicity.

(PDF emailed within 1 workday: $29.90)

Accession: 046009101

Download citation: RISBibTeXText

PMID: 8090141


Related references

Desferrioxamine ototoxicity evaluation of risk factors in thalassemic patients and guidelines for safe dosage. British Journal of Haematology 73(3): 403-409, 1989

Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B. La Pediatria Medica E Chirurgica 10(5): 503-504, 1988

Desferrioxamine and nicotinamide at insulin dependent diabetes mellitus onset Results after 1 year of follow-up. Diabetologia 37(SUPPL 1): A209, 1994

Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up study. Pediatrics 63(3): 443-450, 1979

Ototoxicity of desferrioxamine in hemodialyzed patients. Acta Otorrinolaringologica Espanola 40(1): 13-16, 1989

Desferioximine induced Ototoxicity in Thalassemic patients. Annals of Neurosciences 17(4): 182-184, 2010

Evaluation of a pilot telephone follow-up clinic project for rheumatology out-patients over a one year period. British Journal of Rheumatology 36(SUPPL 2): 29, 1997

Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. Journal of Pediatric Hematology/Oncology 18(1): 42-45, 1996

Long-term safety of an early ACE-inhibitor treatment of patients with acute myocardial infarction: Results of the 3 year follow-up period on 696 Swiss patients randomized to the ISIS-4 trial. Zeitschrift fuer Kardiologie 89(2): 81-83, 2000

Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18(5): 473-478, 1998

High-dose desferrioxamine as a cause of growth failure in thalassemic patients. European Journal of Haematology 40(4): 380-381, 1988

Results of evaluation of 203 patients for photosensitivity in a 7.3-year period. Journal of the American Academy of Dermatology 33(4): 597-602, 1995

The effect of low dose desferrioxamine on ototoxicity in hemoglobinopathy patients. Beuzard, Y, Lubin, B, Rosa, J, INSERM Colloquium; Sickle cell disease and thalassaemias: New trends in therapy, Colloque INSERM; Sickle cell disease and thalassaemias: New trends in therapy 377-378, 1995

Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica 90(1): 129-131, 2005